alexa Sentinel Lymph Node Biopsy in Vulvar Cancer: What is the Standard of Care? | OMICS International
ISSN: 2476-2261
Journal of Oncology Translational Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Sentinel Lymph Node Biopsy in Vulvar Cancer: What is the Standard of Care?

Lindsey Beffa and Katina Robison*

Program in Women’s Oncology, Department of Obstetrics and Gynecology, Women and Infants Hospital, Alpert Medical School, Brown University, USA

*Corresponding Author:
Katina Robison
MD, Program in Women’s Oncology
Department of Obstetrics and Gynecology
Women and Infants Hospital, Brown University
Providence, RI, USA
Tel: +011-401-274-1100
Fax: +011-401-453-7529
E-mail: [email protected]

Received date: August 12, 2017; Accepted date: August 14, 2017; Published date: August 21, 2017

Citation: Beffa L, Robison K (2017) Sentinel Lymph Node Biopsy in Vulvar Cancer: What is the Standard of Care? J Oncol Transl Res 3:118. doi:10.4172/2476-2261.1000118

Copyright: © 2017 Beffa L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Oncology Translational Research

Abstract

Purpose: The surgical treatment of most vulvar cancers includes a lymph node evaluation. Historically, inguinofemoral lymphadenectomy was performed with significant associated morbidity. Sentinel lymph node biopsy has been studied as an alternative in order to decrease postoperative morbidity. This review summarizes the evidence supporting the use of sentinel lymph node biopsy as standard of care in vulvar cancer. Findings: Sentinel lymph node biopsy has a sensitivity of 92% with a negative predictive value of 97-98%. Combining both radiotracer and dye methods improves the sentinel lymph node detection rate and sensitivity. The rate of groin recurrence and 5-year overall survival are comparable to inguinofemoral lymphadenectomy. Postoperative complications including lymphedema, wound infection and wound separation are significantly lower after sentinel lymph node biopsy. Summary: Sentinel lymph node biopsy for the surgical evaluation of vulvar cancer is feasible, cost-effective, associated with less short- and long-term morbidity when compared to inguinofemoral lymphadenectomy and has comparable rates of survival and groin recurrence. Sentinel lymph node biopsy should be performed as the standard of care for appropriate patients in high-volume centers.

Keywords

Vulvar cancer; Sentinel lymph node; Gynecologic malignancies

Introduction

Vulvar cancer remains an uncommon disease comprising approximately 4% of gynecologic malignancies, with an estimated 6020 new vulvar cancer cases and 1150 vulvar cancer deaths predicted in the United States in 2017 [1]. Surgical resection remains the mainstay of vulvar cancer staging; however, the surgical management strategies have evolved with time. Historically a radical vulvectomy with en-bloc inguinofemoral lymphadenectomy was performed but with significant associated morbidity [2]. The triple incision technique demonstrated less morbidity with comparable survival outcomes and became the standard of care [3]. Sentinel lymph node biopsy, using similar techniques to melanoma and breast cancer surgical lymph node evaluation, is now acceptable and preferable in appropriate patients to decrease morbidity associated with inguinofemoral lymphadenectomy [4].

Vulvar Cancer

Lymph node metastases are the most significant prognostic factor in vulvar squamous cell carcinoma (SCC) demonstrating the continued importance of regional lymph node evaluation at the time of surgical staging [5]. Survival directly correlates with lymph node positivity: patients with negative inguinal lymph nodes have a 5 year survival rate of 96%, compared to 80% in patients with up to two positive lymph nodes and 12% in those with greater than two positive lymph nodes [6]. Complications are seen in the majority of patients who undergo radical vulvectomy with en-bloc inguinofemoral lymphadenectomy. Early complications including wound infection, wound breakdown or necrosis occur in up to 85% of patients and late complications including lower extremity lymphedema occur in up to 70% of patients [7].

The transition to a triple-incision technique in the 1980s was in effort to decrease morbidity associated with radical vulvectomy with enbloc inguinofemoral lymphadenectomy while preserving the survival rates associated with radical surgical excision. While complication rates decreased with this technique, they continued to be significant. Using separate incisions to perform a radical vulvectomy and inguinofemoral lymphadenectomy, wound complication rates of 17-40% are seen for wound breakdown, wound infection, and lymphocyst formation. The rate of lymphedema also remains significant with up to 30% of patients suffering from this late, and potentially permanent, complication. One review demonstrated that 76% of patients had at least one postoperative complication [8]. While imperative to appropriate treatment planning and staging, the degree of lymphadenectomy required during surgical evaluation has come under debate.

The likelihood of groin metastasis is low in early stage vulvar cancer patients, specifically 10-15% of patients with lesions <20 mm will have lymph node metastases [9,10]. Unfortunately clinical examination of groin nodes is inaccurate, with a false negative rate up to 24%; proving the importance of continued lymph node sampling at the time of surgery [11]. Sentinel lymph node biopsy was introduced for vulvar cancer patients in order to evaluate groin lymph nodes while decreasing surgical morbidity, as the majority of patients with early stage vulvar cancer will have negative lymph nodes [5].

Sentinel Lymph Node Biopsy

Initially described in penile cancer in the 1970s, sentinel lymph node biopsy has been used in other cancer types for decades in order to identify patients who may require additional lymph node dissection [12]. Sentinel lymph node biopsy became the standard of care in the treatment of melanoma and breast cancer in the 1990s [13,14]. DiSaia et al. described sentinel nodes in vulvar cancer in the late 1970s, being inguinal nodes above the cribriform fascia. It was noted that if these superficial lymph nodes were free of metastatic disease, the risk of identifying positive deep groin or pelvic lymph nodes was low [15]. Levenback et al. [16] initially described the feasibility of performing sentinel lymph node biopsy in vulvar cancer in 1994 and since that time multiple additional studies have been conducted to confirm the feasibility of this technique [17-22].

Sentinel lymph node dissection uses the concepts that within a regional lymph node basin, there is a consistent and orderly pattern to lymphatic drainage and that the first lymph node(s) act as a filter for migrating tumor cells [23]. Therefore, if the sentinel lymph node(s) is negative, the remainder of the lymph nodes within that lymph node basin should be negative. Dissecting fewer lymph nodes for accurate evaluation of lymph nodes metastases is one of the greatest benefits of sentinel lymph node biopsy. Different techniques for performing sentinel lymph node biopsy have been studied including injection of radioactive tracer technetium-99 m sulfur colloid (Tc-99 m) and injection of blue dye. Pathologic assessment of sentinel lymph nodes should involve ultra-staging and staining with hematoxylin and eosin (H&E) [24].

A meta-analysis performed by Hassanzade et al. [25] reviewed 49 studies that used blue dye, radiotracer, or both mapping methods and confirmed that sentinel lymph node dissection was an appropriate and accurate technique to surgically evaluate groin lymph nodes in the treatment of vulvar cancer. Pooled detection rates for sentinel lymph node per patient were 94.4% and per groin was 84.6%. Pooled sensitivity per patient and groin were each 92% with 8% false negative rates. The pooled negative predictive values were 97% per patient and 98% per groin. This meta-analysis identified that mapping method impacted the detection and sensitivity of sentinel lymph nodes and concluded that combining radiotracer and blue dye methods yields the highest detection rates and sensitivity. Midline tumors were found to have higher false negative results compared to lateral tumors; and those patients with palpable inguinal lymph nodes had lower sensitivity and detection rates [25].

The GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) included patients with unifocal vulvar cancer measuring less than 4cm and allowed those with negative sentinel lymph node to be followed, while those with positive sentinel lymph nodes then underwent inguinofemoral lymphadenopathy. The study design of GROINSS-V differed from prior studies in that many of previous studies performed sentinel lymph node biopsy followed by inguinofemoral lymphadenopathy to determine the negative predictive value of sentinel lymph node dissection [26]. This study demonstrated that patients with negative sentinel lymph nodes had low rates of groin recurrence, minimal morbidity from the sentinel lymph node procedure and excellent survival [27].

The rate of groin recurrence following sentinel lymph node biopsy has been evaluated as groin recurrences are correlated with high mortality rates. The groin recurrence rate following superficial inguinofemoral lymphadenopathy has been reported at 5-7% [28- 30]. The GROningen INternational Study of Sentinel nodes in Vulvar cancer (GROINSS-V-I) reported a groin recurrence rate of 2.9% [27]. Additional studies have confirmed low rates of groin recurrence following sentinel lymph node biopsy alone, including Robison et al. who reported a groin recurrence rate per patient of 5.2% following sentinel lymph node biopsy alone [31-35]. A population-based analysis performed by Rottman et al. reported that despite an increase in the use of sentinel lymph node biopsy over a 16 year period from 11.4% to 39.1%, there was no change in local recurrence (19%), lymph node recurrence (9%) or 5 year overall survival (55%) [36]. This data suggests that patients treated with sentinel lymph node biopsy alone will have similar risk of groin recurrence and no change in overall survival.

Postoperative complications were also lower with sentinel lymph node biopsy compared to inguinofemoral lymph node dissection, depicted in Figure 1. In patients treated with sentinel lymph node biopsy alone, lymphedema has been reported between 2-9% and 7% of patients had wound complications including wound infection, lymphocyst or wound separation [27,31]. Additionally, sentinel lymph node biopsy has been associated with an improvement in quality of life [36].

guidelines-oncology-lymph-node

Figure 1: Complication rates based on lymph node dissection approach [8,27,31].

Studies evaluating the cost effectiveness of sentinel lymph node biopsy for vulvar cancer have shown that compared to inguinofemoral lymphadenectomy, sentinel lymph node biopsy has decreased cost, in addition to being associated with decreased length of hospital stay [37]. Sentinel lymph node biopsy became an alternative standard of care procedure presented in the National Comprehensive Cancer Network vulvar cancer treatment guidelines [38]. It is currently recommended that sentinel lymph node biopsy be performed by a high-volume surgeon as some studies have suggested improved detection rates based on surgeon experience performing sentinel lymph node biopsy [26,27]. The GROINSSV- II study only allowed enrollment at centers experienced in sentinel lymph node biopsy and will help to answer the question regarding the appropriate management of positive sentinel lymph nodes. The management of positive sentinel lymph nodes is currently under debate, but may include adjuvant radiation with or without inguinofemoral lymphadenectomy. GROINSSV- II is evaluating recurrence rates in patients with positive sentinel node metastasis <2 mm and treating these patients with radiation while omitting inguinofemoral lymphadenectomy [31,39,40]. The results of GROINSSV- II will hopefully help to determine the best treatment course for these patients.

Conclusion

Numerous studies have demonstrated the benefit of sentinel lymph node biopsy in the surgical treatment of vulvar cancer. In centers with experienced surgeons, sentinel lymph node biopsy should be considered standard of care and an alternative to inguinofemoral lymphadenectomy in patients with negative clinical groin examination and unifocal tumor measuring <4 cm. To increase the sentinel lymph node detection rate and sensitivity, both radiocolloid and dye are recommended for mapping. If the primary tumor is 2 cm or greater from the midline, a unilateral sentinel lymph node biopsy is appropriate. For a primary tumor within 2 cm of the midline, a bilateral sentinel lymph node biopsy is recommended. In the event that a sentinel node is not identified, inguinofemoral lymphadenectomy is recommended [26,38]. Sentinel lymph node biopsy is feasible, cost-effective and associated with decreased morbidity and wound complications; all while showing no negative impact on groin recurrence or survival.

Conflict of Interest

The authors have no conflict of interest.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Journals

Recommended Conferences

Article Usage

  • Total views: 126
  • [From(publication date):
    September-2017 - Dec 12, 2017]
  • Breakdown by view type
  • HTML page views : 105
  • PDF downloads : 21
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version